ORLANDO, Fla., June 15, 2016 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, today announced that it has retained Maxim Group LLC, a leading investment banking, securities and investment management firm, to provide strategic corporate planning and investment banking services to the company. Maxim will focus on strategies to maximize shareholder value through its full scope of investment banking services.
“Engaging Maxim is paramount in the company's maturation that will enable the strategic positioning of Immune Therapeutics for investors and, in turn, increase its capacity to reach as many people who will benefit from its proprietary immune therapy,” said Immune Therapeutics Chief Executive Officer, Noreen Griffin.
Ritesh Veera, Managing Director of Maxim Group, commented, "We are delighted to partner with Immune Therapeutics, Inc. in the financial and value creation components of its corporate strategy through our full-service investment banking capabilities. We are looking forward to working with Immune Therapeutics to assist with strategic planning, developing strategic partnerships, advising on potential acquisitions and introducing the company to the investment community."
About Maxim Group LLC
Maxim Group LLC is a leading full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed income and derivative sales & trading, equity research and prime brokerage services to a diverse range of corporate clients, institutional investors and high net worth individuals. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission and the Municipal Securities Rulemaking Board (MSRB), and is a member of the following: Financial Industry Regulatory Authority (FINRA), Securities Insurance Protection Corporation (SIPC), NASDAQ Stock Market and NYSE Arca, Inc. To learn more about Maxim Group, visit www.maximgrp.com.
About Immune Therapeutics, Inc.
Immune Therapeutics, Inc. [F/K/A TNI Biotech, Inc.] is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using our patented immunotherapy. Its products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Its proprietary technology, therapies, and patents include the treatment of a wide range of cancers. The most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and our Low Dose Naltrexone product (LDN) or Lodonal™, which have been shown to stimulate the immune system even in patients with advanced cancer.
Even though management considers any condition that results in altered-immune response a target for investigation, we will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by Immune Therapeutics may not proceed as contemplated, and by all other matters specified in Immune Therapeutics’ filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. Immune Therapeutics does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Immune Therapeutics' filings with the Securities and Exchange Commission, including its recent periodic reports.
Investor and Media Contact: Phillip Sugarman, Vice President Investor Relations Investor Relations Partners Phone: 818-280-6800 firstname.lastname@example.org
Source:Immune Therapeutics, Inc.